On the other hand, clinical trials testing C1-INH supplementation in addition to standard of care (SOC) in patients with non-critical SARS-CoV-2 pneumonia showed no clinical advantage in preventing COVID-19 progression when using a recombinant human C1 inhibitor (ConA) [38]. Here, SERPING1 is linked to COVID-19.